You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. PlusOne: Prototyping and Validation of a Wireless In-Home Breathing Monitor for Prevention of Overdose Deaths

    SBC: Xandem Technology LLC            Topic: NIDA

    DESCRIPTION provided by applicant This proposal investigates the use of a novel passive personal monitoring system to stem the tide in the epidemic of deaths due to unintentional opioid drug overdoses In the U S in opioid drug overdoses including prescription pain relievers and heroin caused deaths a number that has increased dramatically over the past two decades A person w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing

    SBC: Clinacuity, Inc            Topic: 400

    DESCRIPTION provided by applicant The adoption of Electronic Health Record EHR systems is growing at a fast pace in the U S and this growth results in very large quantities of patient clinical data becoming available in electronic format with tremendous potentials but also equally growing concern for patient confidentiality breaches Secondary use of clinical data is essential to fulfill ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Natural product inspired antibacterials with unique ribosomal binding

    SBC: Curza Inc            Topic: NIAID

    Project Summary The long term objective of this project is to develop a new class of broad spectrum antibiotics focused on Gram negative bacteria Inspired by a natural product this class targets an unexploited binding site of the bacterial ribosome With ever increasing reports of resistance to frontline therapies addressing Gram negatives there is a critical need for new therapies yet very ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. New therapeutics targeting skeletal excessive Fe for thalassemia major bone loss

    SBC: NANOMEDIC INC            Topic: NICHD

    DESCRIPTION provided by applicant This is a SBIR Phase I application to develop new iron chelating drugs for prevention and treatment of iron overload induced bone loss in patients with thalassemia major TM a rare disease in the US Virtually all TM patients are affected by osteopenia and osteoporosis and these skeletal complications herald and contribute to a general clinical deterioratio ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Routinizing HIV testing for Adolescents

    SBC: MEDIA REZ LLC            Topic: NICHD

    DESCRIPTION provided by applicant This study will aim to assess the feasibility and acceptability of using state of the art social media and game technology to increase HIV testing among adolescents and young adults AYA ages Rates of HIV testing among AYA are low resulting in high proportions of AYA who are positive or unaware of their HIV infection Further public health messages wh ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. New Peptide Reagent for Imaging Denatured Collagen in Histopathology

    SBC: 3HELIX INC            Topic: 200

    DESCRIPTION provided by applicant Helix Inc proposes to develop a new peptide based tissue staining agent for detecting denatured collagen in histopatholgical studies in this Phase I SBIR The founders of Helix Inc Drs Yang Li and Michael Yu discovered a synthetic Collagen Hybridizing Peptide CHP which can specifically bind to the denatured collagen molecules with high affinity the ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government